The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine

Djimdé, Abdoulaye; Makanga, Michael; Kuhen, Kelli; Hamed, Kamal

doi:10.1586/14787210.2015.1052793

Cited by 16 publications

(11 citation statements)

References 165 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resistance to AL is a growing debate [27, 28]; however this result should be considered with caution, knowing the absence of any biology test prior to anti-malarial use. This implies a possible use of anti-malarials outside the correct indication (i.e.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the knowledge and attitude of pharmacists about the national malaria control policy in southern Benin

Ganfon

Ekanmian²,

Amoussou

et al. 2017

Malar J

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the knowledge and attitude of pharmacists about the national malaria control policy in southern Benin

Ganfon

Ekanmian²,

Amoussou

et al. 2017

Malar J

View full text Add to dashboard Cite

show abstract

“…Among the Artemisinin-based combination therapies, artesunate-amodiaquine (ASAQ), artesunatesulfadoxine-pyrimethamine (ASSP), dihydroartemisinin-piperaquine (DHA/PPQ), artesunate-mefloquine (ASMQ) and AL are the most commonly recommended ACTs for the treatment of uncomplicated falciparum malaria in African countries [11]. Several recent studies have observed that these ACTs have maintained high efficacy (cure rate ≥ 95%) in many of these countries, despite their use for more than a decade [49][50][51]. Nevertheless, a study carried out in Angola from two different regions in 2013 and 2015 showed a lower efficacy (<90% cure rate) of AL.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Artemisinin-lumefantrine for the treatment of uncomplicated malaria after more than a decade of its use in Kenya

Kishoyian

Njagi

Orinda

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Plasmodium falciparum resistance to antimalarial drugs remains to be a major threat to the control of malaria globally. After the deployment of artemisinin-based combination therapy (ACT), there have been reports of reduced sensitivity of the drug to parasite clearance. In Kenya, artemisinin-lumefantrine (AL) is the recommended first-line drug in the treatment of uncomplicated malaria. This study sought to assess the efficacy of AL after its reintroduction in Kenya, a decade later. In this study, we assessed clinical and parasitological responses of children under five years in May and November 2015 in Chulaimbo sub-County, Kisumu, Kenya.Method: Patients of ≥6 and ≤60 months of age with confirmed Plasmodium falciparum mono-infection were enrolled in the study. The patients were treated with a standard dose of AL and followed up for 28 days. During which period we monitored treatment responses and follow-up adherence.Results: Of the 90 patients enrolled, fourteen (14) were lost to follow-up, with 76 completing the study period. Seventy-five patients 75 (98.7%) cleared, parasitemia within 48 hours while one (1.3%) cleared on day 3. There was 100% clinical and parasitological parasite clearance. Conclusion: Artemisinin lumefantrine was found to be highly efficacious to plasmodium falciparum parasites in children aged ≥6 and ≤60 months. Based on this, the drug can be used to treat uncomplicated malaria in the study population. However, there is need for continued monitoring of its effectiveness in children and adults to counter the threat of resistance.

show abstract

“…days [32]. This leads to successive accumulation of the drug after the completion of the full dose su cient enough for the elimination of residual parasites and possibly prevention of new infection [32].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Artemisinin-lumefantrine for the treatment of uncomplicated malaria after more than a decade after its use in Kenya

Kishoyian

Njagi

Orinda

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Plasmodium falciparum resistance to antimalarial drugs remains to be a major threat to the control of the disease globally. After the deployment of artemisinin-based combination therapy (ACT), there have been reports of reduced sensitivity of the drug to parasite clearance. In Kenya, artemisinin-lumefantrine (AL) is the recommended first-line drug in the treatment of uncomplicated malaria. This study sought to assess the efficacy of AL after its reintroduction in Kenya, a decade later. We assessed clinical and parasitological responses of children under five years in May and November 2015 in Chulaimbo sub-County, Kisumu, Kenya. Method: Patients of ≥6 and ≤60 months of age with confirmed Plasmodium falciparum mono-infection were enrolled in the study. The children were inpatient for close monitoring, they were treated with a standard dose of AL under supervision of a qualified nurse and followed up for 28 days. We monitored treatment adherence and responses. Efficacy of artemether lumefantrine on Plasmodium falciparum was determined.Results: Of the 90 patients enrolled, fourteen (14) were lost to follow-up, with 76 completing the study period. Seventy-five patients 75 (98.7%) cleared the parasitemia within 48 hours while one (1.3%) cleared on day 3. There was 100% clinical and parasitological parasite clearance. Conclusion: Artemisinin lumefantrine was found to be highly efficacious to plasmodium falciparum parasites in children aged ≥6 and ≤60 months. The results reported here indicate that the drug can be used to treat uncomplicated malaria in the study population. However, there is need for continued monitoring of its effectiveness in children and adults to counter the threat of resistance.

show abstract

The emerging threat of artemisinin resistance in malaria: focus on artemether-lumefantrine

Cited by 16 publications

References 165 publications

Evaluation of the knowledge and attitude of pharmacists about the national malaria control policy in southern Benin

Evaluation of the knowledge and attitude of pharmacists about the national malaria control policy in southern Benin

Efficacy of Artemisinin-lumefantrine for the treatment of uncomplicated malaria after more than a decade of its use in Kenya

Efficacy of Artemisinin-lumefantrine for the treatment of uncomplicated malaria after more than a decade after its use in Kenya

Contact Info

Product

Resources

About